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introduction: To investigate cortical excitability and synaptic plasticity in amnestic mild 
cognitive impairment (aMCI) using 5  Hz repetitive transcranial magnetic stimulation 
(5 Hz-rTMS) and to assess whether specific TMS parameters predict conversion time to 
Alzheimer’s disease (AD).
Materials and methods: Forty aMCI patients (single- and multi-domain) and 20 
healthy controls underwent, at baseline, a neuropsychological examination and
5 Hz-rTMS delivered in trains of 10 stimuli and 120% of resting motor threshold (rMT) 
intensity over the dominant motor area. The rMT and the ratio between amplitude of 
the 1st and the 10th motor-evoked potential elicited by the train (X/I-MEP ratio) were 
calculated as measures of cortical excitability and synaptic plasticity, respectively. 
Patients were followed up annually over a period of 48 months. Analysis of variance 
for repeated measures was used to compare TMS parameters in patients with those 
in controls. Spearman’s correlation was performed by considering demographic
variables, aMCI subtype, neuropsychological test scores, TMS parameters, and
conversion time.
results: Thirty-five aMCI subjects completed the study; 60% of these converted to AD. 
The baseline rMT and X/I-MEP ratio were significantly lower in patients than in controls 
(p = 0.04 and p = 0.01). Spearman’s analysis showed that conversion time correlated 
with the rMT (0.40) and X/I-MEP ratio (0.51).
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Discussion: aMCI patients displayed cortical hyperexcitability and altered synaptic plas-
ticity to 5 Hz-rTMS when compared with healthy subjects. The extent of these changes 
correlated with conversion time. These alterations, which have previously been observed 
in AD, are thus present in the early stages of disease and may be considered as potential 
neurophysiological markers of conversion from aMCI to AD.
Keywords: mild cognitive impairment, alzheimer’s disease, transcranial magnetic stimulation, cortical excitability, 
synaptic plasticity, N-methyl-d-aspartate acid receptor
that modulates the excitability of neurons (Ridding and Ziemann, 
2010; Vallence and Ridding, 2014). A single TMS pulse applied 
over the primary motor cortex (M1) elicits a motor-evoked 
potential (MEP) in the contralateral target muscles (Pascual-
Leone et al., 1994). The minimal intensity required to induce a 
MEP at rest with an amplitude of at least 50 μV with a probability 
of 50% defines the resting motor threshold (rMT) (Barker et al., 
1985). Single TMS pulses delivered in trains are the principle of 
repetitive TMS (rTMS). This technique yields effects that may 
outlast the stimulus train and vary from inhibition to facilitation 
depending on the stimulus parameters adopted, and in particular 
on the frequency. Trains of low-frequency rTMS delivered at 1 Hz 
or below are believed to transiently depress synaptic efficiency, 
an effect that resembles that underlying long-term depression 
(Pascual-Leone et al., 1998). By contrast, high-frequency rTMS 
(hf-rTMS) (≥1 Hz) can transiently enhance cortical excitability 
and plasticity in a fashion resembling glutamate-dependent neu-
rotransmission (Pascual-Leone et al., 1994, 1998; Jennum et al., 
1995; Berardelli et  al., 1998; Modugno et  al., 2001; Kobayashi 
and Pascual-Leone, 2003; Inghilleri et  al., 2004, 2005). When 
delivered in healthy subjects at 5  Hz repetitive transcranial 
magnetic stimulation (5  Hz-rTMS) and at a suprathreshold 
intensity over M1, rTMS facilitates cortical excitability, increas-
ing the amplitude of the MEPs during the train (Berardelli et al., 
1998). This facilitation outlasts the train by about 1  s, thereby 
providing evidence of plastic changes in the cortex. These effects 
seem to be related to synaptic long-term potentiation (LTP)-like 
mechanisms and mainly involve the glutamatergic system via the 
activation of postsynaptic N-methyl-d-aspartate acid (NMDA) 
receptors (NMDAr) (Kobayashi and Pascual-Leone, 2003; 
Inghilleri et  al., 2004, 2005). This neurophysiological evidence 
suggests that rTMS may be a suitable tool to study alterations 
in synaptic plasticity and excitability within the human cortex 
(Hoogendam et al., 2010).
In the last two decades, several studies have adopted various 
TMS techniques to assess patterns of neuroplastic changes in 
AD, corroborating findings showing that cortical physiology is 
altered in AD owing to an underlying neurodegenerative process 
that affects cholinergic and glutamatergic neurotransmission (Di 
Lazzaro et al., 2002, 2004, 2006; Inghilleri et al., 2006; Nardone 
et  al., 2006, 2008; Alberici et  al., 2008; Pennisi et  al., 2011). In 
particular, 5  Hz-rTMS has provided useful information on 
various aspects of altered glutamatergic neurotransmission in 
patients with AD (Inghilleri et al., 2006), regardless of cholinest-
erase inhibitor (AChEI) chronic intake (Trebbastoni et al., 2012). 
Consistent evidence points to decreased rMT, which reflects 
increased cortical excitability, and altered synaptic plasticity to 
inTrODUcTiOn
Mild cognitive impairment (MCI) may be considered as the 
intermediate stage between the expected cognitive decline of 
normal aging and the pathological decline of dementia. Several 
definitions of MCI have been proposed since the 1960s and many 
terms have been adopted in the literature to describe MCI (Kral, 
1962; Reisberg et al., 1982; Flicker et al., 1991; Levy, 1994; Ebly 
et al., 1995). In 1999, Petersen et al. (1999) investigated MCI as a 
prodromal condition for Alzheimer’s disease (AD), highlighting 
the importance of memory complaints in incipient AD in non-
demented subjects. Subsequent work enlarged the definition of 
MCI to include other forms of cognitive impairment that cover a 
range of clinical phenotypes (Winblad et al., 2004).
Mild cognitive impairment may manifest itself through a variety 
of symptoms. When memory loss is the predominant symptom, 
it is termed amnestic mild cognitive impairment (aMCI), with 
the single-domain (aMCIsd) subtype being used when memory 
is the only function affected, and the multi-domain (aMCImd) 
subtype when impaired memory is associated with other deficits 
(Petersen, 2004; Winblad et al., 2004). People with aMCI have the 
highest risk of conversion to AD (Bennett, 2003; Petersen, 2004; 
Petersen et al., 2005; Espinosa et al., 2013).
While all those who progress to AD go through a period of 
MCI, not all MCI leads to AD, with many MCI subjects remain-
ing stable or returning to normality (Mitchell and Shiri-Feshki, 
2009). Data on outcomes following a diagnosis of MCI suggest 
that the annual conversion rate to AD in clinical studies varies 
greatly from 10–15% (Bennett, 2003; Petersen, 2004; Petersen 
et al., 2005; Farias et al., 2009) to 41% (Geslani et al., 2005). The 
main research challenge in this field consists in identifying, from 
among individuals with a diagnosis of MCI, those who convert 
to AD, particularly those who do so more rapidly, in order to be 
able to treat the disease more promptly.
Several excellent studies have been designed to find the most 
predictive biosignature of AD pathology in MCI by investigat-
ing structural, functional, and molecular neuroimaging and 
cerebrospinal fluid essays of amyloid-beta (Aβ) and tau proteins 
(Hampel et al., 2008; van Rossum et al., 2010; Drago et al., 2011). 
Few works have instead studied electrophysiological biomarkers 
in MCI.
Transcranial magnetic stimulation (TMS) is a low-cost, non-
invasive electrophysiological technique that can be used to study 
the mechanisms underlying cortical excitability and synaptic 
plasticity in vivo (Pascual-Leone et al., 1994; Berardelli et al., 1998; 
Romeo et al., 2000). It is based on the principle of electromagnetic 
induction of an electric field through the brain (Barker et al., 1985) 
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rTMS as the consequences of glutamatergic system impairment 
in AD (Alagona et al., 2001; Ferreri et al., 2003; Di Lazzaro et al., 
2004; Farlow, 2004; Inghilleri et al., 2006; Trebbastoni et al., 2012).
Dysfunctional glutamatergic neurotransmission, particularly 
that mediated by the NMDAr, has been studied in AD (Mota et al., 
2014) though not yet in MCI. The neuropathological evidence of 
a striking pathology-dependent pattern of glutamatergic synaptic 
remodeling in both AD and MCI due to AD (Bell et al., 2007; 
Schaeffer and Gattaz, 2008) suggests that functional alterations 
in glutamatergic neurotransmission may already be detected 
in vivo in MCI. The hypothesis that these functional abnormali-
ties may precede the development of AD and might emerge in the 
preclinical stages of the disease is the rationale of this research 
on patients with a diagnosis of MCI. The main aim of our study 
was, indeed, to investigate glutamatergic system functioning in 
MCI by evaluating cortical excitability and synaptic plasticity 
using 5 Hz-rTMS in subjects with a diagnosis of aMCI compared 
with healthy controls. Furthermore, since the data available on 
rTMS and other TMS techniques used as diagnostic tools in MCI 
(Sakuma et al., 2007; Nardone et al., 2012, 2014; Terranova et al., 
2013) are scanty and contrasting, and no works have yet investi-
gated the prognostic power of these techniques in predicting the 
clinical outcome in aMCI patients, the second aim of our study 
was to investigate any correlations between baseline responses 
to 5  Hz-rTMS, clinical characteristics and neuropsychological 
test scores and the timing of conversion to AD in a 4-year long 
longitudinal study.
MaTerials anD MeThODs
subjects
The study was conducted on 40 right-handed patients, consecu-
tively recruited at the Department of Neurology and Psychiatry 
of the “Sapienza” University of Rome Umberto I Hospital, with a 
diagnosis of single- or multi-domain aMCI according to Petersen’s 
revised diagnostic criteria (Petersen, 2004; Winblad et al., 2004), 
and 20 healthy controls. The 12-month recruitment period ran 
from January to December 2007. We enrolled male or female 
patients with the following characteristics: age between 50 and 
80  years; a self-reported history of subjective memory decline, 
corroborated by an informant, with gradual onset and slow pro-
gression over the previous year; an objective memory impairment 
as observed during the neuropsychological evaluation; a mini-
mental state examination (MMSE) (Folstein et  al., 1975) score 
≥24; a clinical dementia rating scale (CDR) (Morris, 1993) score 
of 0.5 with a memory box score ≥0.5; with a geriatric depression 
scale (GDS) short-form (van Marwijk et al., 1995) score ≤6; with 
complete functional abilities of daily living as confirmed by a 
caregiver and measured by the activity of daily living scale (ADL) 
and the instrumental activity of daily living scale (IADL) (Lawton 
and Brody, 1969); with normal levels of serum vitamin B12, 
folate, and thyroid hormones; with a low cerebrovascular risk 
with no signs or symptoms of severe hypertension, heart disease, 
dyslipidemia, or diabetes; with a modified Hachinski ischemic 
scale (HIS) ≤4; with a magnetic resonance imaging scan (MRI) 
of the brain performed within the previous 6 months showing no 
evidence of moderate or severe chronic ischemic cerebrovascular 
disease rated visually on axial FLAIR images using the Fazekas 
scale (Fazekas et al., 1987). Only patients whose Fazekas scales 
were less than grade 2 were included. Healthy controls consisted 
of volunteers who had no neurological or psychiatric symptoms 
and a normal MRI of the brain. They were included if cognitive 
functioning was normal, as assessed by a MMSE ≥28/30 and a 
CDR = 0. To avoid the potential effects of any drugs on the elec-
trophysiological parameters studied, any subjects taking drugs 
affecting the central nervous system, such as antidepressants, 
antipsychotics, anticonvulsants, AChEI, or any other dietary 
supplement indicated in the symptomatic treatment of MCI, were 
excluded.
The study was performed in compliance with the international 
rights of the patient and in accordance with the Declaration of 
Helsinki of 1990. The local ethics committee approved the experi-
mental procedures used. All the subjects could understand and 
carry out the tasks required during the stimulation procedure and 
gave their written informed consent to participation in the study.
stimulation Technique
The TMS stimulation paradigm complied with the safety regula-
tions currently recommended for TMS studies (Rossi et al., 2009). 
TMS was delivered through a high-frequency magnetic stimula-
tor (Magstim Rapid  –  The Magstim Company Ltd., Whitland, 
South West Wales, UK) connected to a figure-of-eight coil placed 
over the motor area of the dominant hemisphere. Biphasic mag-
netic pulses were delivered over the primary motor area of the 
dominant hemisphere to find the optimal position for eliciting a 
MEP in the contralateral first dorsal interosseous (FDI) muscle. 
The coil was held tangentially to the scalp with the handle point-
ing back and away from the midline at 45°. The motor threshold 
was calculated at rest and was considered as the lowest intensity 
able to evoke a MEP of more than 50 μV in at least 5 out of 10 
consecutive trials in the FDI muscle. Electromyographic activity 
was recorded through a pair of surface silver/silver chloride (Ag/
AgCl) disk electrodes placed over the contralateral FDI muscle. 
Electromyographic signals were recorded and filtered through 
a Digitimer D360 amplifier (Digitimer Ltd., UK) (bandwidth 
20 Hz–1 kHz) and analyzed off-line. MEPs were recorded at rest. 
During rTMS, participants were asked to relax the FDI muscle 
throughout the TMS trains. In order to ensure relaxation in the 
target muscle, participants were provided with visual and audi-
tory feedback of EMG activity in the FDI. In all the subjects, 
rTMS was delivered in 10 trains of 10 stimuli, at a 5-Hz frequency 
and a stimulation intensity of 120% rMT. The inter-train interval 
was 2 min. The size of the MEPs evoked by rTMS was measured 
peak-to-peak. To quantify the percentage increase in the MEP 
size (MEP facilitation) during the train delivered at a 5-Hz fre-
quency, we calculated the ratio between the amplitude of the 10th 
and the 1st MEP evoked by the train of stimuli (X/I-MEP ratio) 
(Inghilleri et al., 2006).
study Design
Figure 1 shows the study design. All the participants underwent 
a physical examination, neurological assessment, and blood 
samples for laboratory tests at baseline (T0). Blood pressure and 
FigUre 1 | study design. At the baseline (T0), all the participants enrolled underwent a neuropsychological evaluation (NPS), a physical examination (PE), blood 
samples (Lab), and 5 Hz-rTMS. The cohort of aMCI subjects then started the longitudinal observational period. At each time point, the patients were reassessed in 
order to determine whether they had converted to dementia. Subjects who fulfilled the diagnostic criteria for aMCI (non-converters) at each time point continued the 
study to the subsequent follow-up visit. Converters were instead excluded from the study.
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pulse were also measured. Subjects with aMCI also underwent 
a comprehensive neuropsychological evaluation (Van Gorp 
et al., 1986; Basso et al., 1987; Orsini et al., 1987; Spinnler and 
Tognoni, 1987; Carlesimo et  al., 1996; Giovagnoli et  al., 1996; 
Novelli et al., 1996; Caffarra et al., 2002, 2011; Appollonio et al., 
2005), including Rey’s auditory verbal learning test (RT), the 
corsi block-tapping test (CT), Rey’s complex figure test (RCFT), 
the digit-span task (DS), the visual-search matrix test (VS), the 
trail-making test part A (TMT-A) and B (TMT-B), the Boston 
naming test (BNT); the token test (TT), verbal semantic fluency 
tests (VSF), verbal phonemic fluency tests (VPF), the clock draw-
ing test (CDT), the frontal assessment battery (FAB), and Raven’s 
progressive colored matrices (RCPM). Patients and controls also 
underwent the MMSE, ADL, and IADL scales. 5 Hz-rTMS was 
the last experimental procedure applied at T0 in a separate session 
within 1 week of the clinical and neuropsychological evaluation.
The aMCI cohort was clinically followed up every 12 months 
(±1  month) over a period of 48  months. During the study, 
neither AChEI nor other substances to treat cognitive disorders 
were administered. At each follow-up visit (T1, T2, T3, and T4), 
patients underwent a clinical examination, blood testing, vital 
signs measurements, HIS scale, and a new neuropsychological 
assessment in order to assess whether conversion to AD had 
occurred. The clinical diagnosis of AD was made according 
to the National Institute of Neurologic and Communicative 
Disorders and Stroke-Alzheimer’s Disease and Related Disorders 
Association (NINCDS–ADRDA) criteria (McKhann et al., 1984). 
Patients who displayed steady, enhanced, or impoverished cogni-
tive functioning but still fulfilled the criteria for MCI during re-
assessments were considered as non-converters and continued in 
the study. Those who displayed worsened cognitive functioning 
with impaired autonomy levels in the activities of daily living that 
fulfilled the NINCDS–ADRDA criteria for a diagnosis of AD were 
instead included in the converters group and were consequently 
excluded from the study.
statistical analysis
Age, rMT, amplitude of first MEP, and I/X MEP ratio in the 
aMCI patients and healthy controls were analyzed by means of 
t-tests for independent variables. MEP amplitudes across trains of 
stimuli were analyzed by means of a repeated measures analysis of 
variance (ANOVA), with factors “group” and “number of stimuli” 
as main factors. Bonferroni’s correction was applied for multiple 
comparisons. To investigate the value of selected neurophysi-
ological parameters (rMT, X/I-MEP ratio) as clinical descriptors 
and indicators of disease progression in aMCI patients, we first 
performed a t-test for independent variables between converters 
and non-converters. Then, we performed a correlation analysis 
in converters (stratified for time of conversion during follow-up 
evaluation) for non-parametric data (Spearman) considering age, 
education, time between the onset of memory complaints and 
the diagnosis of aMCI, aMCI subtype, altered scores at baseline 
neuropsychological tests, and time of conversion to AD. Time of 
conversion was expressed in 12-month intervals (12, 24, 36, and 
48 months).
The significance threshold was set at p < 0.05. Unless otherwise 
stated, results are expressed as means ± SD.
resUlTs
No side effects or adverse events related to the application of the 
electrophysiological stimulation procedures were reported.
Forty aMCI patients and 20 healthy controls were enrolled. 
Thirty-five (20 aMCIsd/15 aMCImd) of the 40 aMCI subjects 
completed the study, and their data were consequently included 
in the statistical analysis. Five patients were lost to follow-up at 
T1. Table 1 shows the baseline clinical, neuropsychological, and 
socio-demographic data of the participants.
Twenty-one subjects (60%) converted to dementia over the 
study period. All the converters fulfilled the NINCDS–ADRDA 
criteria for probable AD. Table 2 shows the converters’ baseline 
TaBle 1 | Demographic, clinical, and neuropsychological data of patients 
and controls (cTr) at baseline.
cognitive 
function 
explored
aMci (inghilleri et al., 2006) cTr 
(romeo 
et al., 2000)aMcisd 
(romeo et al., 
2000)
aMcimd 
(hampel et al., 
2008)
Age 74.9 ± 3.4 73.4 ± 4.0 71.3 ± 6.7
Sex (male/female) 14/6 8/7 9/11
Education (years) 8.6 ± 3.9 6.4 ± 4.5 8.0 ± 3.9
Symptoms onset 
(months)
28.6 ± 15.7 22.2 ± 8.5 –
MMSE 27.1 ± 1.4 26.5 ± 1.7 29.6 ± 1.3
Range (min–max) 25–28 24–29 28–30
RT learning M 25.8 ± 2.9a 22.1 ± 2.8a
Range (min–max) 19–28 17–27
RT recall M 2.7 ± 1.5a 1.7 ± 1.7a
Range (min–max) 0–5 0–5
CT M, V 4.5 ± 1.5 4.25 ± 1.6
RCFT immediate 
recall
M 7.9 ± 2.6 7.4 ± 2.0
RCFT delayed 
recall
M 6.8 ± 2.1 6.6 ± 1.9
DS A 5.5 ± 2.0 5.4 ± 2.1
VS A 35.7 ± 3.1 33.9 ± 3.2
TMT-A A 55.5 ± 3.1 56.8 ± 3.0
TMT-B A 100.7 ± 5.2 97.6 ± 6.1
BNT L 34.0 ± 11.4 27.2 ± 8.1
VPF L 30.2 ± 9.1 20.6 ± 4.9
VSF L 33.4 ± 6.7 25.3 ± 8.8
TT L 40.2 ± 10.2 40.0 ± 12.3
RCFT copy V 30.2 ± 7.6 28.5 ± 6.4
CDT M, V 1.0 ± 0.0 1.8 ± 1.8
FAB F 16.8 ± 0.8 14.9 ± 1.7
RCPM F 42.1 ± 6.5 38.9 ± 5.5
Thirty-five aMCI subjects completed the longitudinal observational study. The 
neuropsychological battery used tests to evaluate cognitive performances in memory 
(M), attention (A), language (L), visuo-spatial functions (V), and frontal functions (F). The 
test battery included Rey’s auditory verbal learning test (RT), the corsi block-tapping 
test (CT), Rey’s complex figure test (RCFT), the digit-span task (DS), visual-search 
matrix test (VS), the trail-making test part A (TMT-A) and B (TMT-B), the Boston naming 
test (BNT); the token test (TT), verbal semantic fluency tests (VSF), the verbal phonemic 
fluency tests (VPF), the clock drawing test (CDT), the frontal assessment battery (FAB), 
Raven’s progressive colored matrices (RCPM), and the mini-mental state examination 
(MMSE). Neuropsychological test scores are expressed as means ± SD.
aPathological scores.
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test scores compared with those obtained at the time of conver-
sion. When divided into the 2 subgroups, 10 (50%) of the aMCIsd 
and 11 (73.3%) of the aMCImd converted to AD. The mean 
conversion rate to AD in our sample was 15% per year when the 
aMCI patients were considered as a whole, and 12.5 and 18.3% in 
the aMCIsd and aMCImd subgroups, respectively.
No significant differences in age or in years of education were 
observed between patients (mean age: 74.4 ±  4.1  years; mean 
education: 7.5 ± 4.3) and controls (mean age: 70.7 ± 9.1 years; 
mean education: 8.0 ± 3.9) (p > 0.05). rMT was significantly lower 
in patients (56.8 ± 9.6) than in controls (64.1 ± 9.7) (p = 0.04), 
whereas no significant difference was observed between the two 
groups in the amplitude of the first MEP (patients 0.6 ±  0.6, 
controls 0.5 ± 0.3, p > 0.05). The X/I-MEP ratio was significantly 
lower in patients (1.2 ± 1.2) than in healthy controls (2.4 ± 1.1) 
(p = 0.01).
Repeated measures ANOVA for MEP amplitude across 5 Hz 
trains revealed a significant effect of factor “group,” with a lower 
MEP amplitude in aMCI patients [F(1, 53) = 5.8852, p = 0.01871], 
and a significant effect of factor “number of stimuli” [F(9, 
477) =  17.741, p =  0.00000]; a significant interaction of factors 
“group” and “number of stimuli” also emerged [F(9, 477) = 13.115, 
p = 0.00000]. Bonferroni’s correction showed that while there was 
no significant change in MEP amplitude across trains in the MCI 
patients, a significant increase in MEP amplitude was detected in 
healthy controls from the seventh stimulus onward (Figure 2).
We then selected the two neurophysiological variables (rMT 
and X/I-MEP ratio) that showed significant differences between 
MCI patients and healthy controls, to investigate possible differ-
ences between converters to AD (in the clinical 4-year follow-up 
study) and non-converters. T-test for independent variables 
showed no significant differences (rMT converters 55.2 ±  9.3, 
non-converters 61.1 ± 11.1, p > 0.05; X/I-MEP ratio converters 
1.2 ± 1.5, non-converters 1.1 ± 0.7, p > 0.05).
Spearman’s correlation analysis was performed in converters 
and showed that age significantly correlated with the baseline 
MMSE score (−0.62), that the baseline score in the RT learning 
test correlated with the aMCI subtypes (−0.58), with a higher 
score being observed in the single-domain group, and that the 
time of conversion to AD correlated with MMSE score at baseline 
(0.43), years of education (0.44) and with the two selected neu-
rophysiological variables, i.e., the rMT (0.48) and X/I-MEP ratio 
(0.60) (Figure 3). No other significant correlations were detected.
DiscUssiOn
The application of 5  Hz-rTMS in patients with a diagnosis of 
aMCI revealed altered synaptic plasticity and cortical excitability, 
as shown by the reduction in the rMT and X/I-MEP ratio, when 
compared with healthy controls. Furthermore, these alterations 
significantly correlated with the time of conversion to AD in 
those patients that did convert during the follow-up.
Few previous works have investigated cortical excitability 
in the earlier stages of AD, including MCI, and the results of 
those that have are inconclusive (Sakuma et al., 2007; Nardone 
et al., 2008). All of these works were cross-sectional studies and 
adopted a range of TMS techniques on small-size samples. Our 
prospective study complements published data in this field by 
revealing a decreased rMT in aMCI patients. Similar results that 
have emerged from several previous studies were interpreted 
as the electrophysiological correlate of cortical glutamatergic 
dysfunctions in AD (Di Lazzaro et al., 2003a,b, 2004; Inghilleri 
et al., 2006). Many of these studies found that reduced rMT was a 
marker of increased motor cortex excitability in moderate AD (de 
Carvalho et al., 1997; Alagona et al., 2001; Di Lazzaro et al., 2002, 
2003a, 2004, 2006; Pennisi et  al., 2002; Inghilleri et  al., 2006). 
Most authors agree that the cortical hyperexcitability described in 
AD is caused by the overactivation of glutamate-dependent intra-
cortical excitatory circuits rather than by deficient intracortical 
inhibitory systems (Di Lazzaro et al., 2003a, 2004). Our findings 
showing that the rMT is decreased in aMCI suggest that a state 
FigUre 2 | average motor-evoked potential (MeP) amplitude across 
trains of 5 hz-rTMs in the two groups. Vertical bars denote 0.95 
confidence intervals. Repeated measures ANOVA showed a significant 
interaction of factors “Number of Stimulus” (x-axis) and “Group” (healthy vs. 
aMCI). Bonferroni’s correction revealed that while there was no significant 
difference across stimuli in the MCI group, there was a significant increase in 
MEP amplitude in healthy controls from the seventh stimulus onward.
TaBle 2 | converters’ MMse, aDl, iaDl, and rT scores obtained at baseline (T0) and at the time point of conversion (conv).
aMci type conversion 
time point
MMse aDl iaDl rT learning rT recall
T0 conv T0 conv T0 conv T0 conv T0 conv
1 sd T1 25 19 6 5 5 4 27 19 4 0
2 sd T2 27 21 6 4 5 3 25 17 5 0
3 sd T2 25 20 6 5 5 3 28 17 2 0
4 sd T2 27 20 6 4 5 3 22 18 1 1
5 sd T3 25 20 6 5 8 4 26 20 4 1
6 sd T3 27 21 6 4 5 3 19 10 0 0
7 sd T3 28 20 6 5 5 2 28 22 4 2
8 sd T3 28 24 6 5 5 4 28 23 2 2
9 sd T4 27 22 6 5 5 3 28 20 4 0
10 sd T4 29 20 6 4 5 4 28 20 2 0
11 md T1 29 22 6 3 8 3 24 19 5 1
12 md T1 24 19 6 3 8 3 22 15 2 0
13 md T1 25 20 6 4 5 3 20 12 0 0
14 md T1 25 22 6 4 5 3 27 25 0 0
15 md T2 27 23 6 5 8 4 23 19 3 0
16 md T2 27 20 6 4 8 6 21 17 3 0
17 md T2 28 23 6 4 8 4 17 10 0 0
18 md T3 27 19 6 4 5 3 20 17 0 0
19 md T3 24 20 6 4 8 5 24 16 3 0
20 md T4 28 22 6 5 5 3 25 16 1 0
21 md T4 28 21 6 4 5 3 20 16 2 0
Mean 26.7 20.9 23.9 17.5 2.2 0.3
SD 1.6 1.4 3.5 3.8 1.7 0.7
sd, single-domain; md, multi-domain; SD, standard deviation.
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of hyperexcitability of M1 already exists in the preclinical stages 
of the disease, months before conversion to AD. We speculate 
that altered glutamatergic functioning, which has previously been 
described as a potential functional compensatory mechanism in 
AD (Niskanen et al., 2011), may start in the early stages of the 
disease, and even be found in the MCI stage.
With regard to cortical plasticity within M1, we observed that 
the application of 5  Hz-rTMS in healthy controls induced the 
expected MEP facilitation, with a progressive increase in the MEP 
amplitude occurring during the train, whereas repetitive stimu-
lation had no effect in subjects with aMCI, in whom the MEP 
amplitude remained stable throughout stimulation. The absence 
of 5 Hz-rTMS-induced MEP facilitation in aMCI subjects’ points 
to an impairment of the mechanisms underlying the induction of 
cortical synaptic plasticity in patients. These findings are in con-
trast to those previously observed in AD patients, in whom the 
same stimulation paradigm elicited a series of MEPs whose ampli-
tude progressively decreased over the train of stimuli (Inghilleri 
et al., 2006). The altered progression of the MEPs over the train 
during repetitive stimulation in the aMCI group reveals an initial 
impairment of the mechanisms that underlie glutamate-induced 
synaptic potentiation. Interestingly, the extent of the alteration 
of these responses, as quantified by the baseline X/I-MEP ratio, 
correlates with the timing of conversion during follow-up, with 
more marked alterations in early converters. Since 5 Hz-rTMS-
associated MEP facilitation resembles an experimental model of 
STP that is largely dependent on the activation of postsynaptic 
NMDAr (Castro-Alamancos and Connors, 1996; Baudry and 
Lynch, 2001; Inghilleri et al., 2004, 2005; Malenka and Bear, 2004), 
we hypothesize that the lack of MEP facilitation observed in aMCI 
depends on the initial impairment of NMDA-dependent cortical 
glutamatergic neurotransmission, which in turn leads to the inef-
ficacy of short-term forms of enhancement in synaptic activity. 
FigUre 3 | scatter plots of resting motor threshold (rMT) (a), X/i-MeP ratio (B) and time of conversion to aD in the 21 converters. Spearman’s rank 
correlation index (rs) is shown for each variable.
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Furthermore, the fact that the steady increase in MEP amplitude 
over the train of stimuli in aMCI patients who subsequently 
converted to AD differs from that previously described in the 
literature in AD patients (Inghilleri et al., 2006) suggests that the 
extent of the glutamate-dependent STP alterations we observed 
may be related to the stage of disease, i.e., marked in AD patients, 
in whom the absence of facilitation is associated with a progres-
sive decrease in the MEP amplitude over the TMS train, and mild 
or incipient in MCI patients, in whom the absence of facilitation 
instead occurs without any significant decrease in MEP amplitude 
from the 1st to the 10th stimuli. The physiopathological correlates 
of these findings might hence depend on a specific dysfunction 
in NMDAr-dependent glutamatergic neurotransmission. This 
hypothesis is in keeping with previous studies that investigated 
synaptic plasticity and cortical excitability in response to TMS 
in healthy subjects using substances that interact directly with 
NMDAr (Höffken et al., 2013). Di Lazzaro et al. (2003b) demon-
strated that ketamine reduces rMT, increases cortical excitability, 
and counteracts synaptic facilitation by progressively reducing the 
MEP amplitude induced by rTMS. These drug-induced responses 
are similar to those we observed in aMCI subjects. Since ketamine 
acts through the selective blockade of NMDAr, followed by an 
increase in non-NMDA neurotransmission, we speculate that a 
similar condition of imbalanced neurotransmission between the 
NMDA and non-NMDA systems, which favors non-NMDA acti-
vation, may occur in the brain of patients with aMCI. The fact that 
the amplitude of the first MEP recorded during 5 Hz-rTMS was 
normal in both patients and controls lends further support to a 
possible functional imbalance toward non-NMDA transmission, 
e.g., α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid 
(AMPA) transmission. Indeed, the first MEP recorded mainly 
depends on activation of the AMPA receptor system (Di Lazzaro 
et al., 2003b, 2004), which appears to be spared in the preclinical 
stages and late stages of AD (Inghilleri et al., 2006).
Several studies supports the notion that synaptic plasticity 
is necessary for learning and memory (Martin et al., 2000) and 
activity-dependent NMDAr-associated synaptic plasticity is a 
prominent feature of the hippocampus (Neves et al., 2008). The 
hippocampus is a crucial component of the medial temporal 
lobe memory circuit. It is affected deeply and early in AD (Braak 
et al., 1998) and its degeneration leads to memory complain and 
prevents the acquisition of new episodic memories (Moodley and 
Chan, 2014). Aβ42 accumulation, the hallmark of AD pathogen-
esis, perturbs hippocampal LTP, decreases spine density and 
disrupts memory-related synapse function (Varga et  al., 2015) 
since the early stages of AD (Hanson et al., 2015). Even though 
the causes that underlie NMDAr involvement in AD are largely 
unknown, multiple lines of evidence suggest that some of the 
deleterious effects of Aβ42 can be directly mediated by NMDAr 
widely in the brain (Scheuer et al., 1996). Aβ42 oligomers have 
been shown to interact with numerous regulatory proteins and 
directly with NMDAr, thereby causing synaptic dysfunctions 
(Braak et al., 1998; Neves et al., 2008; Moodley and Chan, 2014; 
Varga et  al., 2015) and reducing glutamatergic neurotransmis-
sion (Moodley and Chan, 2014). In turn, NMDAr activation 
stimulates Aβ42 production (Scheuer et al., 1996; Hanson et al., 
2015), which reduces the efficacy of glutamatergic transmission 
(Moodley and Chan, 2014) by facilitating the internalization 
of NMDAr (Danysz and Parsons, 2012). All these events may 
lead, in the early stages of the disease, to reduced functioning 
of NMDA receptors expressed in the synapses (Schaeffer and 
Gattaz, 2008; Shankar et  al., 2008). In 2007, in a post-mortem 
immunohistochemical study, Bell and co-workers observed a 
paradoxical increase in glutamatergic presynaptic bouton density 
in persons with MCI due to AD. The authors speculated that an 
increase in presynaptic glutamatergic terminals indicates a type 
of compensatory up-regulation designed to counter the effects 
of pre-existing Aβ42-induced synaptotoxicity, or that the up-
regulated terminals are indicative of an uncoordinated aberrant 
response that is not representative of concerted synaptic plasticity 
(Bell et al., 2007). In keeping with these hypotheses, our results 
in aMCI patients point to the functional inefficacy of attempts by 
the synapses to restore synaptic functioning and plasticity in the 
preclinical stages of the disease.
Another interesting finding of our research is that the altered 
rMT value and X/I-MEP ratio correlated with the conversion 
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time to AD. Among aMCI patients who converted to AD, those 
with worse baseline TMS responses appear to be those who devel-
oped AD earlier. Higher cortical excitability and more severely 
impaired cortical synaptic plasticity, as demonstrated by lower 
rMT levels and lower X/I-MEP ratio, respectively, point to a more 
severe functional impairment, which in turn leads to more rapid 
progression to dementia. Since rMT and the X/I-MEP ratio did 
not correlate with one another, it may be presumed that these 
two TMS variables measure two independent phenomena, both 
of which are linked to glutamatergic system dysfunction.
The positive correlation between conversion time and base-
line MMSE score and conversion time and years of education 
is another suggestive finding of our research. Early converters, 
in fact, seem to obtain lower scores at the baseline MMSE and 
to have a lower educational level than those that did convert 
later during the follow-up. These data are in line with previous 
works investigating neuropsychological (Arevalo-Rodriguez 
et al., 2015), clinical, and demographic (Tokuchi et al., 2014) 
predictors of conversion from MCI to AD. Interestingly, the 
Spearman analysis did not reveal any correlations between the 
rMT and the X/I-MEP ratio and the other variables studied 
including the MMSE score and the years of education. This 
finding suggests that neurophysiological parameters behave as 
independent variables in the prediction of early conversion to 
AD in aMCI.
Although further studies on larger samples are needed to 
confirm our preliminary data, the possibility that 5 Hz-rTMS may 
be used in aMCI patients to identify subjects likely to develop AD 
within a relatively short period of time is appealing. Patients with 
a diagnosis of aMCI due to AD could, by means of 5 Hz-rTMS, 
be classified as early or late potential converters on the basis of 
TMS responses. This information might prove useful not only 
in clinical practice but also for research purposes by offering the 
opportunity to conduct controlled randomized trials to evaluate 
the efficacy of new disease modifying therapies on the clinical 
progression of MCI patients with different neurophysiological 
phenotypes.
The strengths of this work include the high adherence rate to a 
strict protocol and the prospective design. The main limitation is 
the relatively small sample size: in our interpretation, this explains 
the lack of significant results in the comparison of altered TMS 
responses (rMT and X/I-MEP ratio) between converters and 
non-converters. Furthermore, as we did not adopt cerebrospinal 
fluid biomarkers or amyloid PET tracers in our patients, some 
uncertainty surrounding the accuracy of the diagnoses may arise. 
However, in order to reduce to a minimum possibility of including 
patients with preclinical cognitive impairment due to a condition 
other than AD, we only enrolled patients who fulfilled criteria 
that offer the highest predictive power of conversion from aMCI 
to AD in a clinical setting. Additional clinical, neuropsychologi-
cal, and neuroradiological inclusion and exclusion criteria were 
also used to further restrict recruitment only to subjects with 
features often found in persons with a high risk of developing 
AD. The decision to use such highly specific criteria coupled with 
the relatively small number of participants enrolled from among 
the outpatients of a referral memory clinic may explain the high 
rate of conversion to AD in our study sample. A further limitation 
is the lack of follow-up neurophysiological evaluation that could 
provide useful information on the possible progression of the 
observed alterations in TMS responses.
cOnclUsiOn
In conclusion, our data confirm that 5 Hz-rTMS is a non-invasive 
method that can be used in  vivo to study changes in cortical 
excitability and plasticity in patients with cognitive disorders. The 
alterations found in patients with a diagnosis of aMCI may reflect 
a cortical glutamatergic system dysfunction that already exists 
in the prodromal stages of AD. The extent of these alterations 
also appears to correlate with the time of conversion to AD. One 
suggestive hypothesis is that a person with a clinical diagnosis of 
aMCI may be identified as a high or low risk subject for conver-
sion using 5 Hz-rTMS, an electrophysiological technique that is 
widely available and easily applied. Further population-based 
studies on larger numbers of participants are needed to compare 
the specificity and sensitivity of 5  Hz-rTMS as a neurophysi-
ological marker of conversion to AD in MCI with that of other 
pathology-specific biomarkers available for AD.
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